ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs MXN
18.1265
0.00%
Brent Oil
84.155
-0.04%
Bitcoin
61,693.05
-0.18%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) Noticias

VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VRDN
FechaHoraFuenteTítuloSímboloCompañía
11/06/202405:00Business WireViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
10/06/202407:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VRDNViridian Therapeutics Inc
06/06/202415:01Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
31/05/202407:00Business WireViridian Therapeutics Announces Participation in Upcoming June Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
10/05/202407:00Business WireViridian Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
08/05/202406:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
08/05/202406:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
08/05/202406:00Business WireViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
29/04/202407:00Business WireViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VRDNViridian Therapeutics Inc
05/03/202407:00Business WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:VRDNViridian Therapeutics Inc
28/02/202415:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRDNViridian Therapeutics Inc
27/02/202415:01Business WireViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
16/02/202407:00Business WireViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal OfficerNASDAQ:VRDNViridian Therapeutics Inc
14/02/202419:28Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
14/02/202415:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
14/02/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
06/02/202415:01Business WireViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
24/01/202416:12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
19/01/202415:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
17/01/202421:00Business WireViridian Therapeutics Announces Pricing of Public Offering of Shares of Common StockNASDAQ:VRDNViridian Therapeutics Inc
17/01/202415:01Business WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockNASDAQ:VRDNViridian Therapeutics Inc
08/01/202407:00Business WireViridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
04/01/202407:00Business WireViridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
18/12/202310:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
18/12/202306:00Business WireViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
08/12/202315:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRDNViridian Therapeutics Inc
30/11/202315:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VRDNViridian Therapeutics Inc
21/11/202307:00Business WireViridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VRDNViridian Therapeutics Inc
13/11/202315:01Business WireViridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
08/11/202307:00Business WireViridian Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN

Su Consulta Reciente

TG
QH9
ADTRAN
LSE
WNWD
Windward
USOTC
IDCBY
Industrial and Commercia... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados